Relx PLC (NASDAQ:RELX)’s stock had its “outperform” rating reissued by equities researchers at BNP Paribas in a report issued on Monday, ARN reports. Deutsche Bank have set their target price at 730 GBX on its stock. A total of 1.96M shares of the company’s stock traded hands. In October 2013, AstraZeneca PLC announced that MedImmune acquired Spirogen. AstraZeneca, whose earnings have been eroded by competition from cheaper generics, has pledged a return to growth in 2017, and has flagged annual revenues in excess of $45 billion (£29 billion) by 2023. The firm price target would suggest a potential upside of 31.00% from AstraZeneca PLC (LON:AZN)’s previous stock close. The company has a market cap of $84,168 million. This represents a yield of 1.33%.

Astrazeneca PLC (NYSE:AZN): On Friday heightened volatility was witnessed in Astrazeneca PLC (NYSE:AZN) which led to swings in the share price. Most recently, Astrazeneca PLC (NYSE:AZN) reported earnings per share of $0.5 for the fiscal quarter ended on 2015-06-30. Finally, Jefferies Group reaffirmed a “buy” rating and set a GBX 5,400 ($83.41) price target on shares of AstraZeneca plc in a report on Thursday, July 30th.

Zacks uses an average brokerage recommendation (ABR) rating system in order to provide a simplified scale for understanding the calculated average of the actual Buy, Sell, Hold ratings made by research analysts.

AstraZeneca PLC (LON:AZN) is a global biopharmaceutical business. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. The Organization ‘s medicines contain Crestor for handling cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Onglyza for Type 2; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Pulmicort for asthma; Symbicort for asthma and COPD (chronic obstructive pulmonary); Nexium for acid-associated diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in babies.

AstraZeneca’s pipeline has been transformed in recent years, with 15 new drugs now in late-stage development. AstraZeneca operates in over 100 countries, including China, Mexico, Brazil and Russian Federation.